NR2F6 and neoplasm: Importantly, despite the dramatically improved clinical outcome in Nr2f6−/− tumor-bearing mice, no exacerbated signs of irAE were observed in the combinatorial NR2F6/PD-L1 targeting group when directly compared to the mono-therapy mice, suggesting that major side effects might not hamper the therapeutic potential of this combinatorial approach.